The inhibitor-kB kinase-nuclear factor-kB (IKK-NF-kB) and epidermal growth factor receptor-activator protein-1 (EGFR-AP1) pathways are often co-activated and promote malignant behavior, but the underlying basis for this relationship is unclear. Resistance to inhibitors of IKKb or EGFR is observed in head and neck squamous cell carcinomas (HNSCC). Here, we reveal that both IKKa and b contribute to nuclear activation of canonical and alternate NF-kB/REL family transcription factors, and overexpression of signal components that enhance co-activation of the EGFR-AP1 pathway. We observed that IKKa and IKKb exhibit increased protein expression, nuclear localization, and phosphorylation in HNSCC tissues and cell lines. Individually, IKK activity varied among different cell lines, but overexpression of both IKKs induced the strongest NF-kB activation. Conversely, siRNA knock down of both IKKs significantly decreased nuclear localization and phosphorylation of canonical RELA and IkBa and alternative p52 and RELB subunits. Knock down of both IKKs more effectively inhibited NF-kB activation, broadly modulated gene expression and suppressed cell proliferation and migration. Global expression profiling revealed that NF-kB, cytokine, inflammatory response and growth factor signaling are among the top pathways and networks regulated by IKKs. Importantly, IKKa and IKKb together promoted the expression and activity of transforming growth factor a, EGFR and AP1 transcription factors cJun, JunB and Fra1. Knock down of AP1 subunits individually decreased 8/15 (53%) of IKK-targeted genes sampled and similarly inhibited cell proliferation and migration. Mutations of NF-kB and AP1-binding sites abolished or decreased IKK-induced interleukin-8 (IL-8) promoter activity. Compounds such as wedelactone with dual IKK inhibitory activity and geldanomycins that block IKKa/b and EGFR pathways were more active than IKKb-specific inhibitors in suppressing NF-kB activation and proliferation and inducing cell death. We conclude that IKKa and IKKb cooperatively activate NF-kB and EGFR/AP1 networks of signaling pathways and contribute to the malignant phenotype and the intrinsic or acquired therapeutic resistance of HNSCC.
INTRODUCTION
The inhibitor-kappaB kinases (IKKs) mediate signal phosphorylation-induced degradation of inhibitor kappaBs (IkBs), a critical step in releasing the nuclear factor-kappaB (NF-kB) family of transcription factors for cytoplasmic-nuclear translocation, DNA binding and target gene transactivation. 1, 2 The activation of the canonical NFkB pathway is triggered by pro-inflammatory signals through a heterotrimeric complex of the IKKa and IKKb catalytic subunits and the non-catalytic subunit, IKKg. This complex can phosphorylate and degrade IkBs and promote nuclear translocation and phosphorylation of RELA/NK-kB1 (p65/p50). 1, 2 An alternative pathway, regulated by IKKa homodimers, induces processing of the precursor p100 to NF-kB2 (p52) to translocate with RELB. 1, 2 Aberrant activation of IKKs, NF-kB subunits and their regulated gene programs have been implicated in the pathogenesis of many cancers, including head and neck squamous cell carcinomas (HNSCC). 3, 4 Blocking IKK-mediated IkBa degradation and NF-kB activation has been shown to inhibit aberrant gene expression, malignant phenotypes and therapeutic resistance in pre-clinical HNSCC models. 5, 6 Earlier experiments suggested that the IKKb subunit was essential for canonical NF-kB activation through mediation of IkB degradation, 1,2 while IKKa was dispensable for IkB phosphorylation. 7 The importance of IKKb and proteasome in the canonical NF-kB pathway lead to drug development of bortezomib, a proteasome inhibitor that blocks IkB degradation and RELA activation, and MLN-120b, an inhibitor of IKKb kinase activity. 8, 9 However, clinical trials using bortezomib in HNSCC showed limited clinical efficacy, due to incomplete targeting of other NF-kB/REL subunits, and other signaling pathways such as epidermal growth factor receptor (EGFR) and activator protein-1 (AP1), which were shown to contribute to the resistance to bortezomib and radiation in HNSCC. [10] [11] [12] Similarly, our preliminary studies showed that IKKb inhibitors had modest effects in vitro and in pre-clinical HNSCC xenograft models (J Ricker and J Friedman, unpublished observations). Together, these findings suggested that drugs targeting IKKb-mediated activation of NF-kB alone are insufficient and the hypothesis that IKKa may contribute to canonical and/or alternative NF-kB/REL activation and promotion of the malignant phenotype. The few previous studies of IKKa in SCC have emphasized its potential role as a tumor suppressor, reporting increased malignant phenotype with decrease in its expression in poorly differentiated human SCC and in IKKa KO mice. 13, 14 However, we have observed that increased IKKa with IKKb are prevalent in the majority of differentiated HNSCC. How both IKKs together contribute to activation of the NFkB pathway(s) and promoting the malignant phenotype in these cancers remain incompletely understood.
Concurrent with NF-kB activation, the EGFR/AP1 signaling pathway is another important contributor of HNSCC pathogenesis. EGFR and its ligand transforming growth factor a (TGFa) are overexpressed in 490% HNSCC. [15] [16] [17] The EGFR and TGFa genes may be amplified, but are more often overexpressed at the transcriptional level, by unknown mechanism(s) in HNSCC. 18 Together, EGFR and TGFa form an autocrine signaling loop with the mitogen-activated protein kinase/extracellular signalregulated kinase (MAPK/ERK) pathway and activate AP1 transcription factors to promote malignancy. 15, 19 The AP1 transcription factor family of Jun and Fos contains seven members: cJun, JunB, JunD, cFos, FosB, FosL(Fra1) and FosL2(Fra2). 19 We previously observed that co-activation of AP1 in HNSCC, either constitutively or induced through upstream signaling by tumor necrosis factor-a (TNF-a), EGFR and MAPK/ERK or tobacco carcinogens, is mediated through cJun, JunB and Fra1. 15, 16, 20 Nuclear co-activation of NFkB/RELs, and overexpression of EGFR-AP1, was also subsequently linked in oral pre-malignant lesions and HNSCC tumor tissues by immunostaining, 21 but the basis for this association remains undefined. Evidence for cross-talk and co-activation between NFkB and AP1 signaling has been observed in the skin, breast and other solid tumors. [22] [23] [24] To date, the role of IKKa and b in mechanisms of activation of the classical and alternative NF-kB pathways and EGFR/AP1 signaling in human HNSCC remain unclear.
In this study, we observed that both IKKa and IKKb are overexpressed and activated in most HNSCC tumors and cell lines. Cooperatively, they activated NF-kB/REL family members, crossregulated the expression and activities of EGFR/AP1 and promoted proliferation and migration of HNSCC. Consistent with defined genetic studies, dual chemical inhibitors of IKKs or IKKs and EGFR/AP1 more effectively inhibited NF-kB activation, cellular proliferation and survival. Together, our data suggest the critical roles of IKKs as co-regulators of both the canonical and alternative NF-kB pathways and mediators of NF-kB and EGFR/AP1 signaling cross-talk that promote pathogenesis of HNSCC.
RESULTS
Aberrant expression and phosphorylation of IKKa and IKKb in HNSCC tumor specimens and cell lines IKKa and IKKb expression, phosphorylation and localization in HNSCC were examined by immunohistochemical staining of frozen sections of 18 HNSCC and 5 matched mucosa samples ( Figure 1a ). Increased staining of IKKa, IKKb and phospho-IKKa/b was observed throughout malignant epithelia compared with mucosa, which exhibited limited IKK staining in basilar layers (Figure 1a) . The staining intensity and localization of IKKs in tumors were quantified by histoscore. Over 90% exhibited predominantly nuclear IKKa staining, IKKb was detected in both nucleus and cytoplasm and phosphorylated-IKK staining was more intense in the cytoplasm (Figure 1b) . The staining specificity of the antibody for p-IKKa/b was confirmed by immunofluorescence staining after knock down of IKKa, IKKb or both in HNSCC line UMSCC1 (data not shown). Furthermore, IKKa and IKKb protein expression and phosphorylation was increased in the whole cell and nuclear extracts of nine HNSCC lines (UM-SCC) derived from patients with aggressive clinical courses (survival p15 months), 25 compared with primary human keratinocytes (HeKa, Figure 1c) . Thus, these HNSCC cell lines exhibited both IKKa and b expression and p-IKKa/b, consistent with most HNSCC specimens.
Overexpression and activation of IKKa or IKKb enhance IkB degradation and NF-kB signaling in HNSCC cell lines To study the functional roles of IKKs, we overexpressed wild-type (WT) or genetic mutant constructs of IKKs in UM-SCC lines. IKKa and IKKb can be phosphorylated at the Serine phospho-acceptor sites, S176/S180 or S177/181, which were substituted with Alanines (SS-AA) to prevent IKK activation, or with Glutamate (SS-EE) to produce constitutively active IKKs. Catalytically inactive kinases (KA mutants) were produced by Lysine44 substitution with Alanine (K44A, Figure 2a , upper panels). 26, 27 Transfection of all IKK expression vectors increased corresponding IKK protein expression (Figure 2a , lower panels). Overexpression of IKKa or b EE increased kinase activity and decreased IkBa luciferase fusion protein reporter by 490% (Figure 2b ). Conversely, overexpression of kinase-inactive KA plasmids increased IkBa, with IKKb KA mutant exhibiting a stronger dominantnegative effect (Figure 2b) . A higher basal level of NF-kB activity was observed in UM-SCC11B compared with UM-SCC1. IKK WT and IKK EE individually increased NF-kB activation, with IKKb having a greater effect in UM-SCC1 and IKKa in UM-SCC11B (Figures 2c and d) . Co-expression of IKKa and IKKb WT or EE resulted in the highest NF-kB activation in UM-SCC1 but not in UM-SCC11B (Figures 2c and d) . In both the cell lines, IKKa AA had a greater effect in attenuation of NF-kB activity, whereas IKKb KA inhibited NF-kB more than IKKa KA (Figures 2c and d) . Together, these data suggest differential but combinatory roles of IKKa and IKKb in mediating IkBa degradation and NF-kB activation in different HNSCC lines.
Knock down of IKKa or IKKb alone or in combination by siRNA inhibits NF-kB subunit expression, IkBa degradation and NF-kB activation To define the roles of endogenous IKKa and IKKb on NF-kB/REL activation, we knocked down both IKK subunits individually and in combination using siRNAs. We first examined the effects of IKK knock down in UM-SCC1 cells treated with TNF-a, an inducer of canonical signaling which is detected in human HNSCC tumor specimens. 28 The efficacy and specificity of the knock downs were verified in cytoplasmic and nuclear fractions in UM-SCC1 (Figure 3a) . Canonical subunit RELA was modestly inhibited by IKKa or b knock down and was strongly inhibited by dual IKK knock down in both the cytoplasm and nucleus. A similar stepwise reduction from individual to dual IKK inhibition was observed for cytoplasmic phospho-RELA (p-RELA) at Serine536, while individual IKK knock down enhanced nuclear p-RELA relative to basal or dual knock down. The NF-kB1 subunit involved in the canonical pathway, p105 and its processed product p50, were also reduced after IKKa or b individual knock down, while the strongest effects were observed after knock down of both. We detected expression of alternate NF-kB2 p100 protein predominantly localized in the cytoplasm, while processed p52 and RelB predominantly localized in the nuclear fraction (Figure 3a) . Interestingly, expression of the NF-kB subunit p100, and its processed product, p52, were suppressed more by IKKb knock down, while dual knock down was the most effective in inhibiting the nuclear fraction. These protein expression data for p100/p52 can be largely explained by the effects of IKK siRNAs on p100/p52 mRNA, as blocking IKKb exhibited a stronger inhibitory effect on p100/p52 mRNA expression than knock down of IKKa, while knock down of both IKKs exhibited the strongest effects (Figure 3b ). Knock down of IKKs did not significantly affect RELA gene expression (Figure 3b ). These data are consistent with previous observations that the canonical pathway is reported to regulate transcription of the alternate pathway subunit NF-kB2/p100 precursor of p52. 29, 30 In addition, IKKa knock down preferentially inhibited nuclear RelB along with p-p52 at Ser222 (Figure 3a) , a site implicated in p52 dimer and heterodimer formation recently identified by Perkins and colleagues. 31, 32 Further, under TNFa stimulation, we did not detect significant induction of p-p100 (ser866/870), a marker for alternate IKKa pathway signal-mediated processing, in the cytoplasm or nucleus (data not shown). p-IkBa, the downstream target of canonical IKK activation, was more strongly inhibited by IKKb-specific or combinatory knock downs in the cytoplasmic or nuclear fraction. Together, the greater effects of dual inhibition upon the cytoplasmic-nuclear translocation and phosphorylation of NF-kB subunits and IkBa are consistent with predominantly canonical IKKa/b-dependent activation of these subunits in response to inflammatory signaling by TNF-a.
We next examined the functional effects of IKK knock down under Lymphotoxin b (LTb) stimulation (Figures 3c and d ), which is a major upstream signal for alternative NF-kB pathway activation, and detected in lymph nodes to which HNSCC metastasize. 33 LTb induced increased p-p100 in both cytoplasm and nucleus in UM-SCC1. As a consequence, LTb increased p52 in the nucleus. Interestingly, knock down of IKKb decreased p-p100 and p52 more significantly than knock down of IKKa, while knock down of both IKKs blocked p-p100 induced with LTb treatment in both cytoplasm and nucleus. These observations are consistent with above findings, where knock down of IKKb exhibited a stronger inhibitory effect on p100/p52 mRNA and total protein expression than knock down of IKKa, and knock down of both IKKs exhibited the strongest effects. Together, our results provide evidence that in HNSCC, the upstream signaling from both IKKs regulate downstream NF-kB subunits. The effect of IKKb on the p100/p52 is predominantly through its regulatory function controlling p100/p52 gene expression and processing, which is not solely dependent on IKKa-mediated phosphorylation of p-100, consistent with previous findings in other cell types. [34] [35] [36] To assay the functional effect of IKK knock downs on IkB and NF-kB activity, we used IkBa-Luciferase fusion protein ( Figure 3e ) and NF-kB reporter constructs (Figure 3f ). Dual IKK knock down had a greater effect than individual knock downs in different HNSCC cell lines UM-SCC1 (Figures 3e and f), UM-SCC11B ( Figure 3e ) and UM-SCC6 (data not shown). Together, these data indicate that both IKKa and IKKb individually and together contribute to IkBa degradation and NF-kB reporter activation. We examined the relative contribution of canonical and alternate NF-kB/REL subunits on NF-kB reporter activity, which demonstrated significant effects of p65, p105/p50 and RELB knock down (Nottingham L, unpublished observations).
Dual knock down of IKKs suppress a broader gene expression program involving NF-kB, cytokines and growth factor signaling pathways Dual knock down of IKKs showed significant downregulation of genes compared with individual IKK knock down at 48 h using Table S2 ). The interactive networks, established using gene components in cytokines and NF-kB-related pathways (Figure 4c ), or growth factor signaling pathways (Figure 4d ), reveal potential interactive relationships among different molecules and pathways.
Among the knockdown targets, we validated 20 genes by realtime reverse transcriptase-PCR, with the strongest effects observed by dual IKK knock down (Figure 5a ). These include known canonical NF-kB-modulated genes such as IkBa, IL-1 and IL-8, and the non-canonical NF-kB2/p52 subunit gene, established above. Several genes involved in the EGFR/AP1 pathways were suppressed, prompting knockdown experiments with FOSL1, cJun, or JunB (Figure 5b ). Eight of 15 (53%) of IKK target genes were comodulated by AP1 family members, suggesting overlapped as .05) compared with the control. Experiments were performed in triplicate and presented as a mean with s.d. Relative NF-kB reporter activity measured 48 h after overexpression of mutant IKK plasmids in (c) UM-SCC1 and (d) UM-SCC11B cells. Statistically significant differences between individual IKK constructs (*) or dual IKK overexpression (**) with the control plasmid (t-test, Po0.05). KD, kinase domain; NLS, nuclear localization signal; ULD, ubiquitin-like domain; LZ, leucine zipper; HLH, helix-loop-helix; NBD, nemo binding domain. K44, Lysine44; S176/S180, Serine176 and 180; S177/S181, Serine177 and 181.
well as distinct gene targets between IKKs and AP1 signaling pathways. Many of the IKK or AP1 target genes are implicated in cell proliferation and migration, according to Ingenuity Pathway Analysis annotations (Supplementary Table S2 ). Genes in the ERK/ p38/MAPK and PI3 K/AKT pathways involved in cell proliferation include TGFa, HBEGF, EGFR, Jun, JunB, FOSL, EGR1, cyclinD1 and IGFBPs. Genes involved in cell migration included those in the HGF and TGFb signaling pathways, such as EGR1, ETS, Jun, SERPINE1, MMPs, SMADs and their family members. Together, these signaling pathways regulated by IKKs and AP1 family members have previously been implicated as individually important molecules in promoting the malignant phenotype of HNSCC and other cancers.
Knock down of IKKs and RELA inhibit EGFR/AP1 expression as well as AP1 and IL-8 promoter activities To further investigate the specific effects of IKKs and NF-kB signaling on the EGFR/AP1 pathway, we examined the effects of IKK knock downs on EGFR/AP1 protein expression by western blot (Figure 6a ). Individual and dual IKK knock down affected 05 by t-test vs negative control. p-p100 and p52 subunits in (c) cytoplasmic or (d) nuclear fraction were tested after IKK knock down for 44 h and treatment with lymphotoxin beta (a1/b2; 100 ng/ml) for 4 h. (e) Greater IkBa luciferase fusion protein was observed in the double IKK knock down than individual knock downs. (f ) Conversely, the greater combinatory inhibitory effect of NF-kB reporter activity was observed in the IKK double knock down over the single knock downs in UM-SCC1 (left), UM-SCC11B (right) and UM-SCC6 (data not shown). Statistical significance of t-test, *single knock downs compared with negative control: Po0.01; **double knock downs compared with negative control: Po0.001; þ þ dual knock downs compared with single knock downs: Po0.001. expression of EGFR, cJun, JunB and Fra-1/FOSL proteins in whole-cell lysates, consistent with that observed for mRNA expression shown in Figure 5a . To further investigate the role of canonical IKK-mediated regulation of transcription factor RELA in EGFR/AP1 gene regulation, we knocked down RELA by siRNA. A significant decrease in EGFR, JunB and FOSL(Fra1) expression were observed (Figure 6b ), establishing an important role for RELA in co-expression of these EGFR/AP1 pathway components. Consistent with the above observations, knock down of IKKs suppressed AP1 reporter activity at 48 and 72 h (Figure 6c and data not shown). Further, WT IKK-induced proximal IL-8 promoter activity ( À 133 bp from the transcription starting site) was completely abolished by a point mutation at the NF-kB site ( À 83 bp) and partially blocked by a point mutation at the AP1 site ( À 128 bp, Figure 6d ).
Knock down of IKKs and target AP1 genes inhibits cell proliferation and migration The biological roles of IKKa and IKKb on proliferation and migration were examined and demonstrated that dual knock down of IKKs more significantly inhibited cellular proliferation (Figure 7a ). Knock down of IKKb exhibited a greater inhibition of cellular migration than IKKa, while the dual knock down demonstrated the strongest effect (Figures 7b and c) . We examined the effect of knock down of IKK target AP1 subunits on cell proliferation and migration. Knock down of FOSL and JunB individually, but not cJun, significantly inhibited cell proliferation (Figure 7d ; data not shown). Knock down of all AP1 subunits individually suppressed cell migration, with cJun exhibiting the strongest effects (Figures 7e and f) . The data suggest that knock down of both IKKs and target AP1 subunits differentially affect cell growth and migration.
Drugs targeting IKKb, dual IKK and IKK/EGFR/AP1 components differentially inhibit NF-kB activity and cell survival To explore the therapeutic implications of the above findings, we examined the effects of small molecules available for preclinical or clinical studies capable of inhibiting IKKb alone (MLN120b, SC-514), 37 both IKKs (Wedelactone) 38 or IKKa and EGFR/AP1 signaling [heat-shock protein 90 kDa (Hsp90) inhibitor and geldanamycin derivatives, 17-AAG (17-allylamino 17-demethoxygeldanamycin, tanespimycin), 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin, alvespimycin)]. 39 We found that 17-AAG preferentially inhibited IKKa expression in UM-SCC1 and reduced a slower migrating IKKb band in both the cell lines (Figure 8a phospho-p65 in UM-SCC11B cells (Figure 8a ). Hsp90 inhibitor, 17-DMAG, more potently inhibited the NF-kB reporter than MLN-120b in UM-SCC1 cells, while UM-SCC11B cells were sensitive to both the drugs (Figure 8b ). 17-DMAG and Wedelolactone more potently inhibited cell proliferation in both the cell lines, compared with IKKb selective inhibitors, MLN-120b and SC-514 (Supplementary Figure S2) . Both 17-AAG and Wedelolactone are also strong inducers for cell death as demonstrated by the increased sub-G0 DNA fragmentation and cell-cycle arrest at the G2M phase, decreased cell density and increased cell blebbing and detachment (Figure 8c , and Supplementary Figures S3A  and B) . MLN-120b and SC-514 showed cytostatic effects and an increased vacuolization (Supplementary Figure S3B) . We confirmed that IKKa WT and EE mutants rescued NF-kB reporter activation in cells treated with IKKb selective inhibitor MLN120b, when compared with broader inhibitors, such as 17AAG (data not shown). Altogether, these data suggest that inhibitors with dual IKKa/b or broader activity exhibit more potent effects on IKK and NF-kB protein expression, NF-kB activation and induction of cellcycle arrest and cell death, compared with selective-IKKb inhibitors.
DISCUSSION
In this study, we provide evidence supporting a model whereby both IKKa and IKKb cooperatively activate NF-kB, as well as enhance EGFR/AP1 signaling, to promote the malignant phenotype of HNSCC (Figure 8d ). IKKa and IKKb were aberrantly overexpressed in most tumor tissues and cell lines, indicating their co-expression is prevalent in oncogenesis in differentiated HNSCC (Figure 1) . IKKa was previously implicated as a tumor suppressor of differentiation and IKKb-mediated NF-kB and EGFR/AP1 activation in a smaller subset of undifferentiated human HNSCC and knockout mice. 13, 24, 40 However, when co-expressed, modulating IKKa and IKKb in combination induced the strongest effects on NF-kB activity, although either were found to dominantly modulate NF-kB in different cell lines (Figure 2 ). IKKa and IKKb were both shown to mediate nuclear translocation and activation of canonical NF-kB/REL subunits (Figure 3a) . Although IKKa predominately affected nuclear RELB and p-p52 as expected, IKKb predominantly modulated overall expression of p100/p52 mRNA and protein available for nuclear activation (Figures 3a and b) . Pathway and network analyses indicated a cross-talk between IKK/NF-kB and the EGFR/AP1 signaling pathways (Figure 4) , which was shown to be modulated through the expression and functions of NF-kB targets and EGFR/AP1 molecules (Figures 5-7) . Knock down of AP1 subunits affected an overlapping subset of IKK target genes and inhibited cell proliferation and migration (Figures 5 and  7) . Dual targeting of IKKs either by siRNA or small molecule inhibitors with broader activities showed greater inhibitory effects on cell proliferation, migration, cell-cycle arrest and apoptosis (Figures 7 and 8) . Our data strongly suggest that both IKKa/b are important modulators of signaling upstream of NF-kB activation, and cross-talk promoting co-activation of the EGFR/AP1 pathway, important in pathogenesis and therapeutic targeting of HNSCC.
Previously, the IKKb subunit of the canonical IKK complex was believed to be the predominant kinase responsible for IkBdependent NF-kB activation 7 and promotion of tumorigenesis and metastasis. By utilizing IKK genetic mutant IKK constructs, we demonstrate that the specific impacts and variable potencies of IKKa and IKKb activity differ but cooperate in NF-kB activation in HNSCC. Consistent with the previous paradigm, overexpressing kinase-dead mutant IKKb KA had a relatively greater effect compared with IKKa KA in blocking IkBa degradation or NF-kB activation, but constitutively active IKKa or b EE mutants both promoted IkB degradation and NF-kB activation (Figures 2b-d) , indicating IKKa potentiates activation. The activating effects of overexpression of IKKa WT and EE mutants, or inhibitory effects of IKKa AA mutants, together further support the role of signalactivated IKKa in potentiating IKKb activation of NF-kB. These results are consistent with previous reports that IKKa can enhance IKKb activity, though IKKb is the stronger, direct kinase for downstream canonical NF-kB activation. 1, 26 Interestingly, UMSCC11B demonstrated a stronger effect of IKKa WT or EE overexpression (Figure 2c, d ), but greater sensitivity to IKKb inhibitor MLN-120b (Figures 8a and b) , consistent with its constitutively predominant IKKb activation.
Further results modulating IKKa, IKKb or both by siRNA support the hypothesis that endogenous IKKa and IKKb cooperatively regulate nuclear canonical and alternative NF-kB/REL subunits and functional NF-kB reporter activation. As expected, either IKKa or b partially attenuated canonical nuclear RELA and NF-kB reporter activity, while dual inhibition had the most potent effects ( Figures  3a, e and f) . TNF-a and LTb are often expressed by infiltrating cells in HNSCC and lymph nodes, where HNSCC preferentially metastasize. 28, 41 Interestingly, although overall nuclear RELA was partly inhibited by knock down of either IKK under TNF-a treatment, IKK-dependent phosphorylation of nuclear RELA ser536 was enhanced unless both were knocked down, a phenomenon observed when IKKa or b compensate upon knock out of either kinase in mice and human cell lines. 40, 42 Overall and nuclear p100 and p52 were also inhibited with IKKb siRNA (Figure 3a) , which is consistent with previous findings that IKKb strongly regulates TNF-a-induced p100/p52 gene expression (Figure 3b) . 29, 43 LTb, as an alternate pathway inducer, was shown to induce detectable p-p100 and nuclear p52, but IKKb and dual knock down still attenuated p-p100 and nuclear p52 protein (Figures 3c and d) . Recent observations suggest that expression, processing and nuclear localization of p100/p52 may be more dependent on canonical IKK activation and IkBa degradation than previously appreciated. [34] [35] [36] [43] [44] [45] With canonical signal activation, Scheidereit found that p105 and p100 interact and are co-processed to p50 and p52, and that canonically regulated IkB can co-modulate nuclear translocation of RELB, potentially modifying previous paradigms separating canonical and alternative pathways. 36 Consistent with this possibility, our data show similar effects of IKK knock downs on p105/p50 and p100/p52 (Figure 3a) . Together, our results indicate that dual inhibition of IKKa and b has greatest effects on expression, processing, nuclear localization and functional activation of canonical and alternate NF-kB/RELs in HNSCC.
Although our data clearly demonstrate that both IKKa and IKKb co-modulate the NF-kB pathway and expression of many genes, IKKa contains a nuclear localization signal and is capable of modulating gene expression through histone H3 modification, important for NF-kB dependent, and independent gene expression, such as Fos after stimulation with EGF. 46 We found that IKKa was localized in both nucleus and cytoplasm of human HNSCC and IKKa, b and p65 co-activated EGFR and AP1 subunit gene expression ( Figure 5 ). This is in apparent contrast to nonmalignant epidermis of IKKa knockout mice, where IKKa can repress an autocrine loop of EGFR, ERK and EGFR ligands, potentially through NF-kB-independent mechanisms. 24 Further studies suggested that, where IKKa is decreased, this may promote carcinogenesis primarily through loss of its dual function as a tumor-suppressive component of an otherwise intact TGFb pathway.
14 However, for the majority of HNSCC tumors and cell lines, we have recently shown that TGFb function is attenuated via decreased TGFb receptor expression or downstream responsiveness, and IKKa is overexpressed together with enhancement of NF-kB, as well as EGFR expression and pathway activation. [47] [48] [49] Through global gene analysis, we identified a broad gene program regulated by IKKs individually or in combination ( Figures  4 and 5, Supplementary Figure S1 ). Interestingly, IKK-modulated genes were enriched in several growth factor signaling pathways, including EGFR/AP1 signaling often co-activated and important in the malignant phenotype in HNSCC (Figure 4b , lower panel, Figure 5a ). Knock down of AP1 subunits revealed that AP1 co-modulates a major subset of the IKK-regulated genes. Previously, IKK or NF-kB-modulated expression of AP1 family members was suggested by studies in lipopolysaccharidestimulated B cells, monocytes and dendritic cells, [50] [51] [52] as well as in IKKa knockout mouse embryonic fibroblasts. 46, 53 However, the role and means by which IKK modulates the EGFR/AP1 pathway in HNSCC tumorigenesis has not previously been well elucidated. Our data in established HNSCC cell lines support a model, whereby activated IKKs and RELA can induce co-expression of TGF-a, EGFR and downstream Jun and FosL(Fra1) family members and co-activation of AP1. Interestingly, the three AP1 subunits identified in this study are the same ones we had previously shown to be co-activated with NF-kB in HNSCC. 20 In addition, our data showed that AP1 family members exhibited differential functions to modulate cellular functions, such as proliferation and migration (Figures 7d-f) . Our data suggest that FosL(Fra1) cooperates with cJun or JunB to promote migration and inflammatory cytokine production, 54, 55 extending findings beyond a previous study highlighting cJun's role in promoting cellular proliferation. 19 Knock down of IKKb and cJun exhibited strong effects on cell migration (Figure 7) , consistent with knock down of IKKb affecting cJun mRNA and protein expression more significantly than IKKa (Figures 5 and 6 ). Our data are also supported by recent evidence that activated NF-kB signaling contributes to resistance of EGFR-targeted therapy. 56 Together with our study, this suggests that concurrent suppression of both IKK/NF-kB and EGFR/AP1 signaling could enhance therapeutic targeting of HNSCC.
We found that small molecule inhibitors with broader activity against both IKKs (wedelactone), or IKKs and EGFR (Hsp90 inhibitors), had more potent anti-proliferative and cytotoxic activity than IKKb-specific inhibitors (MLN120b and SC-514; Figure 7c , Supplementary Figures S2 and S3) , consistent with the combined targeting of IKKa and IKKb with siRNA. Geldanamycin derivatives inhibit the HSP90, a molecular chaperone preferentially targeting IKKa degradation over IKKb, and inducing apoptosis in different cancers. 39 Although the chemical drugs 17-AAG/17-DMAG have broader ranges of targets compared with specific siRNA targeting, inhibition of IKKa activity was confirmed by the significant suppression of NF-kB activation induced by transfection with WT and EE IKKa mutants, while IKKa rescued NF-kB inhibitory effects of IKKb selective inhibitor MLN120 (data not shown). Also, 17AAG significantly decreased IKKa protein levels (Figure 8a) , consistent with the drug's known ability to destabilize IKKa and increase its degradation rate. Wedelolactone also inhibits both IKKa and IKKb through modulation of caspases and IkB phosphorylation. 38 By contrast, IKKb-specific inhibitors MLN-120b and SC514 exhibited limited efficacy when evaluated in preclinical studies of multiple cancers, 37, 57 consistent with our observations (Figure 8c , Supplementary Figures S2 and S3 and data not shown). Our data have implications for dual IKKa and b inhibition in chemo-or radiation sensitization. IKK knock down may sensitize cancer cells to chemotherapy-induced apoptosis, 58 while Hsp90 inhibitors analogous to 17-AAG/17-DMAG increase radiation sensitivity both in vitro and in vivo in HNSCC (manuscript in preparation). Our current study challenges the conventional idea of focusing heavily on IKKb-mediated signaling for development of anti-tumor drugs, which have not led to expected efficacies in preclinical studies. The current inhibitors targeting NF-kB signaling are based on previously observed roles of IKKb and the classical NF-kB pathway in transgenic or knockout mouse models. 7 However, the lack of efficacy of these inhibitors in solid epithelial tumors suggest that blockade of IKKb maybe be insufficient. Our data suggest the underlying reasons for the lack of therapeutic efficacy and support our hypothesis that blocking both classical NF-kB pathway mediated by IKKa/b and the alternative pathway mediated by IKKa produces an additive and more complete inhibition of downstream genes and malignant phenotypes.
MATERIALS AND METHODS
Immunohistochemical analysis of HNSCC tissue specimens, western blot, reporter gene assay, MTT assay, flow cytometry, wound-healing assay See Supplementary Materials and Methods.
Cell lines and culture
University of Michigan HNSCC (UM-SCC) cell lines were from T.E. Carey (University of Michigan, Ann Arbor, MI, USA) and cultured under standard growth conditions. Cell DNA was sent for sequence genotyping in 2008 and fall 2010 to compare and verify their unique origin from original stocks, as recently described. 25 The 10 loci analyzed included D3S1358, D5S818, D7S820, D8S1179, D13S317, D18S51, D21S11, FGA, vWA and amelogenin. Human epidermal keratinocytes were obtained from (Invitrogen, Carlsbad, CA, USA) and harvested at less than passage 5. siRNAs and plasmids siRNAs were obtained from IDT (Coralville, IA, USA), multiple siRNAs were individually tested and three duplexes of siRNAs with best knockdown efficiency and specifity for each target were selected and pooled for the experiments (Supplementary Table S1 ). IKK expression and mutant constructs were kindly provided by Dr. Ulrich Siebenlist (NIH/NIAID, Bethesda, MD, USA) and Dr. Michael Karin (UC San Diego, USA), consisting of IKKa and IKKb WT, phosphoacceptor-mutant (SS-AA, Serine to Alanine), constitutively activated (SS-EE, Serine to Glutamic Acid) and kinase-dead (K44A, Lysine to Alanine) vectors. 26, 27 Microarray and gene expression analysis Microarray expression profiling was performed using Illumina Beadchip Array, and data were normalized and summarized in GenomeStudio software (Illumina, San Diego, CA, USA). Genes with 450% decreased expression after IKKa and/or IKKb siRNA knock down were selected and compared with scramble siRNA-treated cells and analyzed in statistical software 'R'. To display the common and unique downregulated genes in different treated samples, three-way Venn diagram was made using VennDiagram package from Bioconductor (http://www.bioconductor.org, hosting provided by Fred Hutchinson Cancer Research Center, Seattle, WA, USA). Ingenuity Pathway Analysis was used to detect the significantly enriched signaling pathways within downregulated genes, and two networks were established using genes involved in depicted pathways.
Chemotherapeutic drugs
17-AAG and 17-DMAG exhibit very similar in vitro activity but have different solubility and toxicity profiles in vivo. 59 The drugs were synthesized by the Radiation Oncology Branch at NCI/NIH and kindly provided by Dr. David Gius. SC-514 is a selective and reversible inhibitor of IkB kinase 2 (IKK2) (IC 50 ¼ 3-12 mM) that displays greater than 10-fold selectivity over 28 other kinases (Cayman Chemical, Ann Arbor, MI, USA). Wedelolactone (a natural compound isolated from the herb Eclipta prostrata) was obtained from Biomol (Plymouth Meeting, PA, USA). MLN-120b was provided by Millennium Pharmaceuticals, Inc. (Cambridge, MA, USA) under a Material Transfer Agreement.
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